RS63608B1 - Pirimidinsko jedinjenje kao inhibitor jak kinaze - Google Patents
Pirimidinsko jedinjenje kao inhibitor jak kinazeInfo
- Publication number
- RS63608B1 RS63608B1 RS20220903A RSP20220903A RS63608B1 RS 63608 B1 RS63608 B1 RS 63608B1 RS 20220903 A RS20220903 A RS 20220903A RS P20220903 A RSP20220903 A RS P20220903A RS 63608 B1 RS63608 B1 RS 63608B1
- Authority
- RS
- Serbia
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- crystalline form
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Dental Preparations (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762577852P | 2017-10-27 | 2017-10-27 | |
| PCT/US2018/057682 WO2019084383A1 (en) | 2017-10-27 | 2018-10-26 | PYRIMIDINE COMPOUNDS AS JAK KINASE INHIBITORS |
| EP18801171.2A EP3672965B1 (en) | 2017-10-27 | 2018-10-26 | Pyrimidine compound as jak kinase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS63608B1 true RS63608B1 (sr) | 2022-10-31 |
Family
ID=64277858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20220903A RS63608B1 (sr) | 2017-10-27 | 2018-10-26 | Pirimidinsko jedinjenje kao inhibitor jak kinaze |
Country Status (38)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202200409T1 (it) | 2017-10-27 | 2022-11-18 | Theravance Biopharma R&D Ip Llc | Composto di pirimidina come inibitore di chinasi jak |
| CA3121408A1 (en) * | 2018-11-30 | 2020-06-04 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Heteroaromatic derivatives for use as regulator, preparation method therefor and use thereof |
| TW202106681A (zh) | 2019-04-24 | 2021-02-16 | 美商施萬生物製藥研發Ｉｐ有限責任公司 | 用於治療皮膚疾病之嘧啶jak抑制劑 |
| WO2020219639A1 (en) | 2019-04-24 | 2020-10-29 | Theravance Biopharma R&D Ip, Llc | Ester and carbonate pyrimidine compounds as jak kinase inhibitors |
| MX2023001259A (es) * | 2020-07-28 | 2023-05-15 | Arcutis Biotherapeutics Inc | Formulaciones tópicas que contienen inhibidor de jak y laureth-4. |
| MX2023002378A (es) * | 2020-08-26 | 2023-05-22 | Nalo Therapeutics | Moduladores de proteinas de la familia de protooncogenes myc. |
| WO2022076771A1 (en) * | 2020-10-08 | 2022-04-14 | Icahn School Of Medicine At Mount Sinai | Compositions for treatment alopecia areata, biomarkers for treatment success, and methods of use thereof |
| TW202311256A (zh) * | 2021-06-18 | 2023-03-16 | 美商基利科學股份有限公司 | 用於治療ｆｘｒ誘發之搔癢之ｉｌ－３１調節劑 |
| JP2024539280A (ja) | 2021-10-25 | 2024-10-28 | カイメラ セラピューティクス， インコーポレイテッド | Ｔｙｋ２分解剤およびそれらの使用 |
| JP2024544404A (ja) | 2021-12-15 | 2024-11-29 | アーキュティス・バイオセラピューティクス・インコーポレーテッド | Ｓｈｒ０３０２の安定な製剤 |
| CN114246938A (zh) * | 2022-01-25 | 2022-03-29 | 中山大学中山眼科中心 | Il-4在制备用于治疗视网膜变性疾病药物中的应用 |
| CN115487301B (zh) * | 2022-11-08 | 2023-07-07 | 四川大学华西医院 | Il-13抑制剂在制备延缓或治疗视网膜色素变性的药物中的用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4919934A (en) | 1989-03-02 | 1990-04-24 | Richardson-Vicks Inc. | Cosmetic sticks |
| DE60128709T2 (de) | 2000-09-15 | 2007-12-27 | Vertex Pharmaceuticals Inc., Cambridge | Triazol-verbindungen als protein-kinase-inhibitoren |
| US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| NZ526468A (en) | 2000-12-21 | 2004-03-26 | Vertex Pharma | Pyrazole compounds useful as protein kinase inhibitors |
| JP2008525422A (ja) | 2004-12-23 | 2008-07-17 | ファイザー・プロダクツ・インク | 抗癌剤として有用な複素芳香族誘導体 |
| DE602006021776D1 (de) | 2005-11-16 | 2011-06-16 | Vertex Pharma | Als kinaseinhibitoren geeignete aminopyrimidine |
| EP2044063A1 (en) | 2006-06-30 | 2009-04-08 | Astra Zeneca AB | Pyrimidine derivatives useful in the treatment of cancer |
| US8222256B2 (en) | 2006-07-05 | 2012-07-17 | Exelixis, Inc. | Methods of using IGFIR and ABL kinase modulators |
| KR20140103972A (ko) | 2011-12-22 | 2014-08-27 | 에프. 호프만-라 로슈 아게 | 세린/트레오닌 키나아제 억제제로서의 2,4-다이아민-피리미딘 유도체 |
| WO2015094803A1 (en) * | 2013-12-16 | 2015-06-25 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
| NO2721710T3 (enExample) * | 2014-08-21 | 2018-03-31 | ||
| CN106687467A (zh) * | 2014-09-30 | 2017-05-17 | 韩美精密化学株式会社 | 高纯度（r）‑9‑[2‑（磷酰甲氧基）丙基]腺嘌呤的制备方法 |
| EP3303348B1 (en) * | 2015-05-28 | 2019-08-07 | Theravance Biopharma R&D IP, LLC | Naphthyridine compounds as jak kinase inhibitors |
| US9938257B2 (en) | 2015-09-11 | 2018-04-10 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
| CA3020506A1 (en) | 2016-04-28 | 2017-11-02 | Theravance Biopharma R&D Ip, Llc | Pyrimidine compounds as jak kinase inhibitors |
| SMT202200409T1 (it) * | 2017-10-27 | 2022-11-18 | Theravance Biopharma R&D Ip Llc | Composto di pirimidina come inibitore di chinasi jak |
| TW202106681A (zh) | 2019-04-24 | 2021-02-16 | 美商施萬生物製藥研發Ｉｐ有限責任公司 | 用於治療皮膚疾病之嘧啶jak抑制劑 |
| WO2020219639A1 (en) | 2019-04-24 | 2020-10-29 | Theravance Biopharma R&D Ip, Llc | Ester and carbonate pyrimidine compounds as jak kinase inhibitors |
-
2018
- 2018-10-26 SM SM20220409T patent/SMT202200409T1/it unknown
- 2018-10-26 SG SG11202001706RA patent/SG11202001706RA/en unknown
- 2018-10-26 AR ARP180103131A patent/AR113803A1/es unknown
- 2018-10-26 JP JP2020523324A patent/JP7218364B2/ja active Active
- 2018-10-26 AU AU2018354370A patent/AU2018354370B2/en active Active
- 2018-10-26 EP EP18801171.2A patent/EP3672965B1/en active Active
- 2018-10-26 CR CR20200180A patent/CR20200180A/es unknown
- 2018-10-26 EA EA202091016A patent/EA202091016A1/ru unknown
- 2018-10-26 CU CU2020000053A patent/CU24671B1/es unknown
- 2018-10-26 RS RS20220903A patent/RS63608B1/sr unknown
- 2018-10-26 TW TW107137865A patent/TWI789446B/zh active
- 2018-10-26 MA MA49956A patent/MA49956B1/fr unknown
- 2018-10-26 KR KR1020207012597A patent/KR102613503B1/ko active Active
- 2018-10-26 CN CN201880068081.5A patent/CN111247142B/zh active Active
- 2018-10-26 MD MDE20200681T patent/MD3672965T2/ro not_active IP Right Cessation
- 2018-10-26 GE GEAP201815340A patent/GEP20227344B/en unknown
- 2018-10-26 WO PCT/US2018/057682 patent/WO2019084383A1/en not_active Ceased
- 2018-10-26 PT PT188011712T patent/PT3672965T/pt unknown
- 2018-10-26 MX MX2020004255A patent/MX2020004255A/es unknown
- 2018-10-26 ES ES18801171T patent/ES2932526T3/es active Active
- 2018-10-26 IL IL274037A patent/IL274037B2/en unknown
- 2018-10-26 LT LTEPPCT/US2018/057682T patent/LT3672965T/lt unknown
- 2018-10-26 US US16/171,693 patent/US10308646B2/en active Active
- 2018-10-26 DK DK18801171.2T patent/DK3672965T3/da active
- 2018-10-26 HR HRP20221221TT patent/HRP20221221T1/hr unknown
- 2018-10-26 GE GEAP202115340A patent/GEAP202115340A/en unknown
- 2018-10-26 PE PE2020000414A patent/PE20201495A1/es unknown
- 2018-10-26 HU HUE18801171A patent/HUE060401T2/hu unknown
- 2018-10-26 PL PL18801171.2T patent/PL3672965T3/pl unknown
- 2018-10-26 SI SI201830770T patent/SI3672965T1/sl unknown
- 2018-10-26 BR BR112020008015-2A patent/BR112020008015A2/pt unknown
- 2018-10-26 CA CA3074034A patent/CA3074034A1/en active Pending
- 2018-10-26 UA UAA202003146A patent/UA125130C2/uk unknown
-
2019
- 2019-04-22 US US16/390,175 patent/US10562894B2/en active Active
-
2020
- 2020-01-08 US US16/737,067 patent/US10774080B2/en active Active
- 2020-03-13 PH PH12020500528A patent/PH12020500528A1/en unknown
- 2020-03-16 ZA ZA2020/01641A patent/ZA202001641B/en unknown
- 2020-04-23 CL CL2020001090A patent/CL2020001090A1/es unknown
- 2020-04-24 NI NI202000032A patent/NI202000032A/es unknown
- 2020-04-27 EC ECSENADI202023795A patent/ECSP20023795A/es unknown
- 2020-05-06 DO DO2020000083A patent/DOP2020000083A/es unknown
- 2020-08-12 US US16/991,268 patent/US10988470B2/en active Active
-
2021
- 2021-03-30 US US17/301,243 patent/US11420965B2/en active Active
-
2022
- 2022-06-30 US US17/855,539 patent/US11814377B2/en active Active
-
2023
- 2023-10-03 US US18/480,442 patent/US12172994B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12172994B2 (en) | Pyrimidine compound as JAK kinase inhibitor | |
| JP7470713B2 (ja) | Ｊａｋキナーゼ阻害剤としてのエステルおよびカルボナートピリミジン化合物 | |
| EP3601283A1 (en) | Fused imidazo-piperidine jak inhibitor compound | |
| JP7482152B2 (ja) | 皮膚疾患の処置のためのピリミジンｊａｋ阻害剤 発明の背景 | |
| JP2019514903A (ja) | Ｊａｋキナーゼ阻害剤としてのピリミジン化合物 | |
| HK40029509B (en) | Pyrimidine compound as jak kinase inhibitor | |
| HK40029509A (en) | Pyrimidine compound as jak kinase inhibitor | |
| EA041115B1 (ru) | Пиримидиновое соединение в качестве ингибитора jak киназы | |
| OA19911A (en) | Pyrimidine compound as JAK kinase inhibitor. |